Navigation Links
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Date:5/3/2012

uch as glucagon-like peptide-1 (GLP-1) that help regulate blood glucose levels. In addition, LX4211 enhances excretion of glucose in the urine, which may also help to reduce the need for insulin, without causing low blood sugar or hypoglycemia. Lexicon expects to have results from an ongoing Phase 2b trial in type 2 diabetes by mid-year 2012.

About the Clinical Trial in Type 1 Diabetes
The initial Phase 2 proof-of-concept study will be a randomized, double-blinded, placebo-controlled trial in approximately 25 adult patients with type 1 diabetes who will receive LX4211 over a one month treatment period. The primary endpoint of the study will be reduction of insulin required with LX4211 as compared to placebo. Secondary endpoints will include multiple measures of blood sugar to show that LX4211 helps to maintain glycemic control during the treatment period. Under the agreement, additional funding could support future Phase 2 trials of LX4211 in type 1 diabetes.

About Type 1 Diabetes
An estimated 1.3 million people in the U.S. have type 1 diabetes, a chronic disease usually caused by autoimmune destruction of insulin-producing beta cells of the pancreas. The resulting decrease in insulin leads to high levels of glucose in the blood, which in turn can lead to acute metabolic complications as well as chronic problems with eyes, kidneys, nervous system and heart. If not properly controlled with insulin therapy, type 1 diabetes can be fatal. Patients with type 1 diabetes are at least 10 times more at risk for cardiovascular disease compared to people without diabetes. The rate of type 1 diabetes incidence among children under the age of 14 is estimated to increase by 3% annually worldwide.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irrita
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... "Cancer Biomarker Market by Tumor (Breast, Lung, Prostate) Type ... Immunoassay) Application (Diagnostic, Drug Discovery, Prognostic) & Geography - ... Biomarkers Market is expected to reach around 17,689.0 Million ... the forecast period of 2015 to 2020. ...
(Date:8/28/2015)... , Aug. 28, 2015  Today, in final ... (CDC) Contact Lens Health Week, 1-800 Contacts is sharing ... found that contact lens wearers who do not properly ... risk for eye infections. Most contact ... lenses, but a clean lens case is sometimes overlooked.  ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ... Report on China,s Ranibizumab Market, 2012-2019" report to ... approved by CFDA to treat wet age- related macular ... of Novartis, is available in the Chinese market. However, ... for the treatment of wet AMD in ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 51-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... Oct. 12, 2011 Endo Pharmaceuticals (Nasdaq: ENDP ... October 27, 2011 and will host a conference call and ... results.   David P. Holveck, president and CEO ... executive vice president of R&D, Alan Levin, executive vice president ...
... the results of a recent statewide survey, more than half ... their (parents,) prescription (Rx) medications, and one in seven parents ... not prescribed for their child. The survey was ... during a briefing at the Massachusetts State House hosted by ...
Cached Medicine Technology:Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011 2More Than Half of Massachusetts Parents Say Their Kids Have Access to Abusable Prescription Drugs in Their Homes 2More Than Half of Massachusetts Parents Say Their Kids Have Access to Abusable Prescription Drugs in Their Homes 3More Than Half of Massachusetts Parents Say Their Kids Have Access to Abusable Prescription Drugs in Their Homes 4
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ) ... Communications Director for InHealth Media. Mr. Spector comes with a wide array ... doing on-air television, producing shows, on air-radio and media relations. , Brian ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple ... digital handwritten signature. , Clinical trial sites can now use audio, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... the American Southwest, experts are worried not just about ... risks both to nearby residents and to those living ... are anecdotal, people on the front lines of health ...
... use, encouraging infants and young children in preschool and ... play, and requiring child care providers to promote healthy ... curb high rates of obesity among America,s youngest children, ... The report recommends steps that should ...
... (HealthDay News) -- Strategies to encourage physical activity, healthy eating ... of obesity among infants, toddlers and preschoolers in the United ... Limiting children,s TV time is a key recommendation. ... 2 to 5 have doubled since the 1980s. About 10 ...
... 2011 A new automated sample preparation system ... platform has been developed for proteomic biomarker discovery ... Research Institute (TGen) and the Biodesign Institute at ... integrated, high-throughput system is a key tool in ...
... , THURSDAY, June 23 (HealthDay News) -- Minimally invasive ... the deep veins compared with traditional surgery, University of ... called venous thromboembolism (VTE), occur in about a quarter ... The benefits of less invasive laparoscopic surgery also include ...
... investigating how to help deaf people, who have received ... Music professor David Nicholls and Dr Rachel van ... Research (ISVR) have secured a 109,000 grant from the ... from the South of England Cochlear Implant Centre, based ...
Cached Medicine News:Health News:Smoke From Wildfires in Southwest May Be Health Hazard 2Health News:Smoke From Wildfires in Southwest May Be Health Hazard 3Health News:Policies that promote healthy eating, activity and sleep are needed to curb obesity in infants, toddlers and preschoolers 2Health News:Policies that promote healthy eating, activity and sleep are needed to curb obesity in infants, toddlers and preschoolers 3Health News:Policies that promote healthy eating, activity and sleep are needed to curb obesity in infants, toddlers and preschoolers 4Health News:Ways to Curb Childhood Obesity Outlined in U.S. Report 2Health News:Less Invasive Colon Surgery Results in Fewer Blood Clots: Study 2Health News:Helping deaf people to enjoy music again 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: